Loading...
XHKG
0690
Market cap64mUSD
Jul 10, Last price  
0.08HKD
1D
-2.33%
1Q
-17.65%
Jan 2017
-45.10%
IPO
-94.24%
Name

Uni-Bio Science Group Ltd

Chart & Performance

D1W1MN
XHKG:0690 chart
P/E
5.25
P/S
0.84
EPS
0.02
Div Yield, %
3.30%
Shrs. gr., 5y
-1.40%
Rev. gr., 5y
22.93%
Revenues
586m
+6.01%
340,894,000869,946,000526,270,000148,286,00076,764,00057,026,00083,333,000102,624,000122,390,636123,364,000146,489,000156,477,000135,258,000209,449,000208,776,000353,405,000440,316,000484,718,000552,980,000586,211,000
Net income
93m
+12.75%
60,316,000198,380,000-508,323,000-454,653,000-185,156,000-102,864,000-69,308,000-366,130,000-56,578,653-59,799,000-55,727,000-279,309,000-138,567,0002,459,000-71,319,000-19,591,00038,512,00070,876,00082,774,00093,327,000
CFO
90m
+35.43%
86,804,00091,214,00073,542,00081,148,000-29,983,000-37,508,000-20,243,00049,991,000-79,702,647-12,595,000-23,691,000-68,605,000-89,000,000-30,749,000-15,474,00012,042,00048,660,00098,849,00066,708,00090,342,000
Dividend
May 28, 20250.00277 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Uni-Bio Science Group Limited functions as an investment holding enterprise primarily engaged in the research, development, manufacturing, and distribution of biological and chemical pharmaceutical products aimed at treating human health conditions across the People's Republic of China. Its existing product range features GeneTime, a prescribed biological medication for promoting wound healing; GeneSoft, an EGF-based eye drop used to address dry eye syndrome, corneal damage, and to assist post-operative recovery; Pinup, a voriconazole tablet designed to combat severe fungal infections; and Bokangtai, a mitiglinide tablet prescribed for managing Type 2 diabetes, alongside Boshutai, an oral anti-diabetic drug tailored for patients with pre-diabetes. Additionally, the company is progressing with the development of several investigational prescription drugs, including rExendin-4 (Uni-E4) for Type 2 diabetes; rhPTH 1-34 (Uni-PTH), targeting osteoporosis in postmenopausal women; and Uni-GLP, a GLP-1 agonist offering a non-insulin treatment alternative for Type 2 diabetes. The firm was established in 2001 and its headquarters are located in Sha Tin, Hong Kong.
URL
https://www.uni-bioscience.com/
IPO date
Nov 12, 2001
Employees
340
Domiciled in
HK
Incorporated in
KY

Valuation

Title
HKD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT